Hawaii Biotech, Inc.'s West Nile Vaccine Shows 100% Protection In Durability Study; Third Study Confirms Vaccine Candidate's Protective Efficacy

HONOLULU--(BUSINESS WIRE)--Aug. 16, 2005--Hawaii Biotech, Inc., a privately held biopharmaceutical company engaged in the research and development of human pharmaceuticals, announced today that in a third study its West Nile vaccine protected 100 percent of test animals from both illness and death after six months when challenged with live West Nile Virus. In contrast, 53.3 percent of the control animals died, and surviving control animals all showed signs of illness. Two previous studies, in which longer term durability was not assessed, also demonstrated 100 percent protection from both illness and death following live West Nile Virus challenge. An additional study examining protection at one year is underway.

Back to news